Karla Hurt

2.4k total citations · 4 hit papers
24 papers, 1.4k citations indexed

About

Karla Hurt is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Karla Hurt has authored 24 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 15 papers in Pulmonary and Respiratory Medicine and 6 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Karla Hurt's work include Advanced Breast Cancer Therapies (10 papers), Cardiovascular Function and Risk Factors (6 papers) and Heart Failure Treatment and Management (4 papers). Karla Hurt is often cited by papers focused on Advanced Breast Cancer Therapies (10 papers), Cardiovascular Function and Risk Factors (6 papers) and Heart Failure Treatment and Management (4 papers). Karla Hurt collaborates with scholars based in United States, Spain and United Kingdom. Karla Hurt's co-authors include Barry A. Borlaug, Christopher M. Kramer, Yi Lu, Milton Packer, George W. Sledge, Masakazu Toi, Peter A. Kaufman, Patrick Neven, Masahiro Murakami and Martin Frenzel and has published in prestigious journals such as New England Journal of Medicine, Circulation and Nature Medicine.

In The Last Decade

Karla Hurt

24 papers receiving 1.3k citations

Hit Papers

The Effect of Abemaciclib Plus Fulvestrant on Overall Sur... 2019 2026 2021 2023 2019 2024 2024 2024 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
    2019 590 citations George W. Sledge, Masakazu Toi et al. JAMA Oncology profile →
  2. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity
    2024 284 citations Milton Packer, Michael R. Zile et al. New England Journal of Medicine profile →
  3. Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure
    2024 63 citations Christopher M. Kramer, Barry A. Borlaug et al. Journal of the American College of Cardiology profile →
  4. Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial
    2024 46 citations Barry A. Borlaug, Michael R. Zile et al. Nature Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Karla Hurt United States 14 690 667 296 278 241 24 1.4k
Kiyoshi Fujinami Japan 19 245 0.4× 442 0.7× 549 1.9× 208 0.7× 160 0.7× 45 1.2k
Mariëtte H.W. Kappers Netherlands 13 248 0.4× 282 0.4× 379 1.3× 75 0.3× 132 0.5× 18 970
Céline Pallaud Switzerland 14 275 0.4× 128 0.2× 235 0.8× 114 0.4× 108 0.4× 33 810
Lisa O’Rourke United Kingdom 12 984 1.4× 468 0.7× 302 1.0× 291 1.0× 31 0.1× 30 1.5k
Loredana Ciuclan United Kingdom 14 171 0.2× 559 0.8× 509 1.7× 171 0.6× 27 0.1× 23 1.3k
Mari Nakabayashi United States 22 292 0.4× 914 1.4× 453 1.5× 455 1.6× 285 1.2× 40 1.5k
Paulina Selaru United States 16 1.4k 2.0× 1.8k 2.7× 819 2.8× 285 1.0× 39 0.2× 27 2.4k
Yasuhito Fujisaka Japan 17 481 0.7× 272 0.4× 247 0.8× 83 0.3× 109 0.5× 51 885
Suguru Shirotake Japan 20 406 0.6× 431 0.6× 209 0.7× 146 0.5× 81 0.3× 89 1.1k
Helen Musgrove United Kingdom 6 415 0.6× 289 0.4× 441 1.5× 158 0.6× 110 0.5× 7 852

Countries citing papers authored by Karla Hurt

Since Specialization
Citations

This map shows the geographic impact of Karla Hurt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Karla Hurt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Karla Hurt more than expected).

Fields of papers citing papers by Karla Hurt

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Karla Hurt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Karla Hurt. The network helps show where Karla Hurt may publish in the future.

Co-authorship network of co-authors of Karla Hurt

This figure shows the co-authorship network connecting the top 25 collaborators of Karla Hurt. A scholar is included among the top collaborators of Karla Hurt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Karla Hurt. Karla Hurt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Borlaug, Barry A., Michael R. Zile, Christopher M. Kramer, et al.. (2025). Impact of Body Mass Index, Central Adiposity, and Weight Loss on the Benefits of Tirzepatide in HFpEF. Journal of the American College of Cardiology. 86(4). 242–255. 5 indexed citations
2.
Lam, Carolyn S.P., Ángel Rodríguez, Ali Aminian, et al.. (2025). Tirzepatide for reduction of morbidity and mortality in adults with obesity: rationale and design of the SURMOUNT ‐ MMO trial. Obesity. 33(9). 1645–1656. 5 indexed citations
3.
Borlaug, Barry A., Michael R. Zile, Christopher M. Kramer, et al.. (2025). HFpEF-ABA score is a more useful enrichment tool than natriuretic peptides in heart failure with preserved ejection fraction. European Heart Journal. 46(43). 4607–4609. 1 indexed citations
4.
Borlaug, Barry A., Michael R. Zile, Christopher M. Kramer, et al.. (2024). Effects of tirzepatide on circulatory overload and end-organ damage in heart failure with preserved ejection fraction and obesity: a secondary analysis of the SUMMIT trial. Nature Medicine. 31(2). 544–551. 46 indexed citations breakdown →
5.
Kramer, Christopher M., Barry A. Borlaug, Dustin Ruff, et al.. (2024). Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure. Journal of the American College of Cardiology. 85(7). 699–706. 63 indexed citations breakdown →
6.
Packer, Milton, Michael R. Zile, Christopher M. Kramer, et al.. (2024). Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity. New England Journal of Medicine. 392(5). 427–437. 284 indexed citations breakdown →
7.
Zile, Michael R., Barry A. Borlaug, Christopher M. Kramer, et al.. (2024). Effects of Tirzepatide on the Clinical Trajectory of Patients With Heart Failure, Preserved Ejection Fraction, and Obesity. Circulation. 151(10). 656–668. 22 indexed citations
8.
Neven, Patrick, Stephen Johnston, Masakazu Toi, et al.. (2021). MONARCH 2: Subgroup Analysis of Patients Receiving Abemaciclib Plus Fulvestrant as First-Line and Second-Line Therapy for HR+, HER2−-Advanced Breast Cancer. Clinical Cancer Research. 27(21). 5801–5809. 7 indexed citations
9.
10.
Tolaney, Sara M., Lesley Fallowfield, Peter A. Kaufman, et al.. (2021). eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer.. Journal of Clinical Oncology. 39(15_suppl). TPS596–TPS596. 1 indexed citations
11.
Neven, Patrick, Stephen Johnston, Masakazu Toi, et al.. (2020). MONARCH 2: Subgroup analysis of patients receiving abemaciclib + fulvestrant as first- and second-line therapy for HR+, HER2- advanced breast cancer.. Journal of Clinical Oncology. 38(15_suppl). 1061–1061. 2 indexed citations
12.
Sledge, George W., Masakazu Toi, Patrick Neven, et al.. (2019). The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2. JAMA Oncology. 6(1). 116–116. 590 indexed citations breakdown →
13.
Scagliotti, Giorgio V., Igor Bondarenko, Tudor–Eliade Ciuleanu, et al.. (2018). A randomized phase 2 study of abemaciclib versus docetaxel in patients with stage IV squamous non-small cell lung cancer (sqNSCLC) previously treated with platinum-based chemotherapy.. Journal of Clinical Oncology. 36(15_suppl). 9059–9059. 8 indexed citations
14.
Laquente, Berta, José A. López-Martín, Donald Richards, et al.. (2017). A phase II study to evaluate LY2603618 in combination with gemcitabine in pancreatic cancer patients. BMC Cancer. 17(1). 137–137. 53 indexed citations
15.
16.
Calvo, Emiliano, Fadi Braiteh, Daniel D. Von Hoff, et al.. (2016). Phase I Study of CHK1 Inhibitor LY2603618 in Combination with Gemcitabine in Patients with Solid Tumors. Oncology. 91(5). 251–260. 33 indexed citations
17.
Scagliotti, Giorgio V., Ramaswamy Govindan, Karla Hurt, & Alan Y. Chiang. (2016). A randomized phase 2 study of abemaciclib versus docetaxel in patients with stage IV squamous cell lung cancer (SqCLC) previously treated with platinum-based chemotherapy.. Journal of Clinical Oncology. 34(15_suppl). TPS9101–TPS9101. 1 indexed citations
18.
19.
Wiechno, Paweł, Bradley G. Somer, Begoña Mellado, et al.. (2013). A Randomised Phase 2 Study Combining LY2181308 Sodium (Survivin Antisense Oligonucleotide) with First-line Docetaxel/Prednisone in Patients with Castration-resistant Prostate Cancer. European Urology. 65(3). 516–520. 50 indexed citations
20.
Weiss, Glen J., Ross C. Donehower, Ramesh K. Ramanathan, et al.. (2012). Phase I dose-escalation study to examine the safety and tolerability of LY2603618, a checkpoint 1 kinase inhibitor, administered 1 day after pemetrexed 500 mg/m2 every 21 days in patients with cancer. Investigational New Drugs. 31(1). 136–144. 41 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kiyoshi Fujinami Breakdown of academic impact, for papers by Mariëtte H.W. Kappers Breakdown of academic impact, for papers by Céline Pallaud Breakdown of academic impact, for papers by Lisa O’Rourke Breakdown of academic impact, for papers by Loredana Ciuclan Breakdown of academic impact, for papers by Mari Nakabayashi Breakdown of academic impact, for papers by Paulina Selaru Breakdown of academic impact, for papers by Yasuhito Fujisaka Breakdown of academic impact, for papers by Suguru Shirotake Breakdown of academic impact, for papers by Helen Musgrove
Rankless by CCL
2026